Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00808288 · ClinicalTrials.gov registry record · Phase 2

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

A Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
405
Enrollment target
20
Study locations

NCT00808288 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases that has completed, run by Pfizer. The registered enrollment target is 405 participants, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00808288, a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
405 participants
Enrollment target
20
Study locations

Study Summary

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Conditions Studied

Pulmonary Disease, Chronic Obstructive Lung Diseases Lung Diseases, Obstructive

Interventions

  • DRUG Placebo
  • DRUG Salmeterol
  • DRUG PF-00610355
  • DRUG PF - 00610355
  • DRUG PF- 00610355

Study Locations (20)

Florida

  • Pfizer Investigational Site - Daytona Beach
  • Pfizer Investigational Site - Ormond Beach
  • Pfizer Investigational Site - Tampa
  • Pfizer Investigational Site - Trinity

Minnesota

  • Pfizer Investigational Site - Fridley
  • Pfizer Investigational Site - Minneapolis
  • Pfizer Investigational Site - Rochester

Ohio

  • Pfizer Investigational Site - Cincinnati
  • Pfizer Investigational Site - Cincinnati
  • Pfizer Investigational Site - Cincinnati

California

  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - Spring Valley

Kansas

  • Pfizer Investigational Site - Overland Park
  • Pfizer Investigational Site - Overland Park

Alabama

  • Pfizer Investigational Site - Fairhope

Colorado

  • Pfizer Investigational Site - Wheat Ridge

Georgia

  • Pfizer Investigational Site - Austell

Trial Details

FieldValue
Enrollment Target 405 participants
Start Date 2010-03
Est. Completion 2010-12
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00808288

The ClinicalTrials.gov registry entry for NCT00808288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (61% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT00808288 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Minnesota, Ohio.

Frequently Asked Questions

What is clinical trial NCT00808288 about?

NCT00808288 is a clinical study titled "A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.". To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

What is the current status of trial NCT00808288?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2010-03. Estimated completion is 2010-12.

What conditions does trial NCT00808288 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive.

What interventions are being tested in trial NCT00808288?

The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), PF-00610355 (DRUG), PF - 00610355 (DRUG), PF- 00610355 (DRUG).

Who is sponsoring clinical trial NCT00808288?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00808288 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Lung Diseases

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.